Suchergebnisse - "Stagno, Fabio"

PubPharm (204)

111

Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients

enthalten in: Leukemia research | 2015

von Breccia, M. | Efficace, F. | Sica, S. | +31

112

Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study

enthalten in: American journal of hematology | 2015

von Mori, S. | Vagge, E. | le Coutre, P. | +22

113

Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival

enthalten in: Leukemia research | 2014

von Breccia, M. | Luciano, L. | Latagliata, R. | +33

CommentIn: Leuk Res. 2014 Oct;38(10):1156-7. - PMID 25113280

114

Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival

enthalten in: Leukemia research | 2014

von Breccia, M. | Luciano, L. | Latagliata, R. | +33

115

IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation

enthalten in: Carcinogenesis | 2014

von Massimino, M. | Consoli, M. | Mesuraca, M. | +12

116

IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation

enthalten in: Carcinogenesis | 2014

von Massimino, M. | Consoli, M. | Mesuraca, M. | +12

117

Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era

enthalten in: American journal of hematology | 2014

von Malagola, M. | Breccia, M. | Skert, C. | +29

118

Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients

enthalten in: PloS one | 2014

von Giallongo, C. | Parrinello, N. | Tibullo, D. | +8

119

Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era

enthalten in: American journal of hematology | 2014

von Malagola, M. | Breccia, M. | Skert, C. | +29

120

Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase : a retrospective study

enthalten in: Drugs & aging | 2013

von Latagliata, R. | Ferrero, D. | Iurlo, A. | +32